Drugs / ABP 692
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06700343 | Jan 2025 → Jan 2027 expected | relapsing-remitting multiple sclerosis | Amgen | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABP 692 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06700343 ↗ |
| Route | Intravenous | “IV infusion” NCT06700343 ↗ |